160 related articles for article (PubMed ID: 16814664)
1. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs.
Hirata A; Minamino T; Asanuma H; Fujita M; Wakeno M; Myoishi M; Tsukamoto O; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Shiraga M; Kitakaze M; Hori M
J Am Coll Cardiol; 2006 Jul; 48(1):176-84. PubMed ID: 16814664
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with erythropoietin and granulocyte colony-stimulating factor enhances neovascularization and improves cardiac function after myocardial infarction.
Xue J; Du G; Shi J; Li Y; Yasutake M; Liu L; Li J; Kong Y; Wang S; Yun F; Li W
Chin Med J (Engl); 2014; 127(9):1677-83. PubMed ID: 24791874
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
Westenbrink BD; Lipsic E; van der Meer P; van der Harst P; Oeseburg H; Du Marchie Sarvaas GJ; Koster J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
Eur Heart J; 2007 Aug; 28(16):2018-27. PubMed ID: 17576662
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
van der Meer P; Lipsic E; Henning RH; Boddeus K; van der Velden J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
J Am Coll Cardiol; 2005 Jul; 46(1):125-33. PubMed ID: 15992646
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia.
Westenbrink BD; Oeseburg H; Kleijn L; van der Harst P; Belonje AM; Voors AA; Schoemaker RG; de Boer RA; van Veldhuisen DJ; van Gilst WH
Cardiovasc Drugs Ther; 2008 Aug; 22(4):265-74. PubMed ID: 18327705
[TBL] [Abstract][Full Text] [Related]
6. Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits.
Yamada Y; Kobayashi H; Iwasa M; Sumi S; Ushikoshi H; Aoyama T; Nishigaki K; Takemura G; Fujiwara T; Fujiwara H; Kiso M; Minatoguchi S
Am J Physiol Heart Circ Physiol; 2013 Apr; 304(8):H1124-33. PubMed ID: 23417861
[TBL] [Abstract][Full Text] [Related]
7. Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model.
Klopsch C; Furlani D; Gäbel R; Li W; Pittermann E; Ugurlucan M; Kundt G; Zingler C; Titze U; Wang W; Ong LL; Wagner K; Li RK; Ma N; Steinhoff G
J Cell Mol Med; 2009 Apr; 13(4):664-79. PubMed ID: 19449462
[TBL] [Abstract][Full Text] [Related]
8. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat.
Hale SL; Sesti C; Kloner RA
J Cardiovasc Pharmacol; 2005 Aug; 46(2):211-5. PubMed ID: 16044033
[TBL] [Abstract][Full Text] [Related]
9. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine.
Kawachi K; Iso Y; Sato T; Wakabayashi K; Kobayashi Y; Takeyama Y; Suzuki H
Heart Vessels; 2012 Jan; 27(1):79-88. PubMed ID: 22038108
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin improves the efficiency of endothelial progenitor cell therapy after myocardial infarction in mice: effects on transplanted cell survival and autologous endothelial progenitor cell mobilization.
Cheng Y; Hu R; Lv L; Ling L; Jiang S
J Surg Res; 2012 Jul; 176(1):e47-55. PubMed ID: 22595018
[TBL] [Abstract][Full Text] [Related]
11. Post-MI treatment with G-CSF and EPO-liposome with SLX repairs infarcted myocardium through EPCs mobilization and activation of prosurvival signals in rabbits.
Yamada Y; Minatoguchi S; Endo N; Kanamori H; Kawasaki M; Nishigaki K; Mikami A; Minatoguchi S
Pharmacol Res Perspect; 2019 Feb; 7(1):e00451. PubMed ID: 30598826
[TBL] [Abstract][Full Text] [Related]
12. Outcome improvement of cellular cardiomyoplasty using triple therapy: mesenchymal stem cell+erythropoietin+vascular endothelial growth factor.
Tavakoli F; Ostad SN; Khori V; Alizadeh AM; Sadeghpour A; Darbandi Azar A; Haghjoo M; Zare A; Nayebpour M
Eur J Pharmacol; 2013 Aug; 714(1-3):456-63. PubMed ID: 23850947
[TBL] [Abstract][Full Text] [Related]
13. Effects of erythropoietin on cardiac remodeling after myocardial infarction.
Nishiya D; Omura T; Shimada K; Matsumoto R; Kusuyama T; Enomoto S; Iwao H; Takeuchi K; Yoshikawa J; Yoshiyama M
J Pharmacol Sci; 2006 May; 101(1):31-9. PubMed ID: 16717399
[TBL] [Abstract][Full Text] [Related]
14. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair.
Zhang D; Zhang F; Zhang Y; Gao X; Li C; Yang N; Cao K
Transpl Int; 2007 Feb; 20(2):174-83. PubMed ID: 17239026
[TBL] [Abstract][Full Text] [Related]
15. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells.
Prunier F; Pfister O; Hadri L; Liang L; Del Monte F; Liao R; Hajjar RJ
Am J Physiol Heart Circ Physiol; 2007 Jan; 292(1):H522-9. PubMed ID: 16997893
[TBL] [Abstract][Full Text] [Related]
16. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial.
Ludman AJ; Yellon DM; Hasleton J; Ariti C; Babu GG; Boston-Griffiths E; Venugopal V; Walker M; Holdright D; Swanton H; Crake T; Brull D; Moon JC; Puranik R; Muthurangu V; Taylor A; Hausenloy DJ
Heart; 2011 Oct; 97(19):1560-5. PubMed ID: 21900585
[TBL] [Abstract][Full Text] [Related]
17. Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.
Gäbel R; Klopsch C; Furlani D; Yerebakan C; Li W; Ugurlucan M; Ma N; Steinhoff G
Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):20-5; discussion 25. PubMed ID: 19380336
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis.
Brunner S; Winogradow J; Huber BC; Zaruba MM; Fischer R; David R; Assmann G; Herbach N; Wanke R; Mueller-Hoecker J; Franz WM
FASEB J; 2009 Feb; 23(2):351-61. PubMed ID: 18827024
[TBL] [Abstract][Full Text] [Related]
19. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit.
Lipsic E; Westenbrink BD; van der Meer P; van der Harst P; Voors AA; van Veldhuisen DJ; Schoemaker RG; van Gilst WH
Eur J Heart Fail; 2008 Jan; 10(1):22-9. PubMed ID: 18077209
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M
Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
